RxDoctor Payments Data

Michael Susano, MD

Psychiatry · Shreveport, LANPI 1063440105

Payments from drug & device makers

$2,749in general payments, 2019–2025

Across 193 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$670
  • Neurocrine Biosciences, Inc.$482
  • AbbVie$445
  • E.r. Squibb & Sons, L.L.C.$205
  • Otsuka America Pharmaceutical, Inc.$198
  • Johnson & Johnson$149
  • plus $599 from 8 others

What the payments were for

  • Food & beverage$2,67497%
  • Education$753%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,749 in reported general payments places this provider in the 75th percentile of 474 psychiatry providers in Louisiana.

See all psychiatry providers in Louisiana

Medicare billing

Part B allowed, 2024
$13,030
Medicare patients
59
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate30$260,023
Invega SustennaPaliperidone Palmitate74$203,034
Austedo XrDeutetrabenazine13$122,479
Invega TrinzaPaliperidone Palmitate17$101,004
CaplytaLumateperone Tosylate30$50,697
LybalviOlanzapine/Samidorphan Malate31$50,421
VraylarCariprazine Hcl27$41,365
AristadaAripiprazole Lauroxil12$28,289
TrintellixVortioxetine Hydrobromide37$21,632
Lurasidone Hcl84$12,523
Clomipramine Hcl21$6,785
Haloperidol Decanoate51$4,503
Vilazodone Hcl34$2,558
Trazodone Hcl265$2,104
Divalproex Sodium ErDivalproex Sodium40$1,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$149$304,03891 claims
Neurocrine Biosciences, Inc.Ingrezza$482$260,02330 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$137$122,47913 claims
Alkermes, Inc.Lybalvi, Aristada$670$78,70943 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$116$50,69730 claims
AbbVieVraylar$445$41,36527 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$21,63237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 psychiatry providers in Louisiana.

Other psychiatry in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →